![Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review | BMC Medical Research Methodology | Full Text Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-021-01260-7/MediaObjects/12874_2021_1260_Fig3_HTML.png)
Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review | BMC Medical Research Methodology | Full Text
![Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults | Scientific Reports Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-48554-x/MediaObjects/41598_2019_48554_Fig1_HTML.png)
Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults | Scientific Reports
![FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-020-01140-9/MediaObjects/41416_2020_1140_Fig2_HTML.png)
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
![Diagram illustrating the study population in the per-protocol study... | Download Scientific Diagram Diagram illustrating the study population in the per-protocol study... | Download Scientific Diagram](https://www.researchgate.net/publication/346490800/figure/fig1/AS:963553221689363@1606740398360/Diagram-illustrating-the-study-population-in-the-per-protocol-study-design-Orange.png)
Diagram illustrating the study population in the per-protocol study... | Download Scientific Diagram
![Figure 2, Forest Plot For ACR20 Responses at Week 24 in SUMMACTA and MUSASHI Studies for the Per-Protocol Population - Tocilizumab (Actemra) - NCBI Bookshelf Figure 2, Forest Plot For ACR20 Responses at Week 24 in SUMMACTA and MUSASHI Studies for the Per-Protocol Population - Tocilizumab (Actemra) - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK349502/bin/sr0374f2.jpg)
Figure 2, Forest Plot For ACR20 Responses at Week 24 in SUMMACTA and MUSASHI Studies for the Per-Protocol Population - Tocilizumab (Actemra) - NCBI Bookshelf
![An Open Label Clinical Trial to Evaluate the Efficacy and Tolerance of a Retinol and Vitamin C Facial Regimen in Women With Mild-to-Moderate Hyperpigmentation and Photodamaged Facial Skin - JDDonline - Journal An Open Label Clinical Trial to Evaluate the Efficacy and Tolerance of a Retinol and Vitamin C Facial Regimen in Women With Mild-to-Moderate Hyperpigmentation and Photodamaged Facial Skin - JDDonline - Journal](http://dl.jddonline.com/articleimages/article_2977/table1.png)
An Open Label Clinical Trial to Evaluate the Efficacy and Tolerance of a Retinol and Vitamin C Facial Regimen in Women With Mild-to-Moderate Hyperpigmentation and Photodamaged Facial Skin - JDDonline - Journal
![Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial](https://ijp-online.com/articles/2021/53/1/images/Indian%20J%20Pharmacol_2021_53_1_6_315079_f1.jpg)
Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial
![Signifience - Intention-to-Treat (ITT) vs. Per Protocol (PP) : How to choose the right clinical trial population Signifience - Intention-to-Treat (ITT) vs. Per Protocol (PP) : How to choose the right clinical trial population](https://www.signifience.com/wp-content/uploads/2022/10/Groupe_people_01_01S-scaled-e1672600105362.jpg)